Beginning of the month Berkshire-Hathaway exceeded the market capitalization of $1 trillion, becoming the primary non-tech company within the US to accomplish that. Soon after Eli Lilly could possibly be the primary healthcare company to hitch this club.
Why? Eli Lilly is benefiting from rising demand for its injectable weight-loss drug Zepbound and diabetes drug Mounjaro, each incretin drugs that mimic hormones produced within the gut to curb appetite and regulate blood sugar. Sales of Mounjaro and Zepbound now account for nearly 40 percent of Eli Lilly's total sales, in line with second-quarter ends in August.
The company is one in every of the 2 dominant players within the weight-loss drug market, which some analysts say could possibly be price $150 billion by the tip of the last decade. Eli Lilly could also overtake its principal investor. Rival, Novo Nordiskbecause it shows progress in expanding the provision of its medicines.
Novo Nordisk can be investing billions to spice up production, but its own weight-loss and diabetes drugs Wegovy and Ozempic missed second-quarter sales expectations, partly on account of price pressure within the US.
Investors are also encouraged by the opposite potential health advantages of Eli Lilly's treatments, which could boost their long-term sales potential. The company has released several study results over the past yr demonstrating Zepbound's potential as a treatment for obesity-related conditions reminiscent of obstructive sleep apnea, fatty liver disease and heart problems.
Eli Lily shares have risen over 60% this yr, bringing the corporate's market value to just about $900 billion.
And the corporate could soon reach that trillion-dollar mark. Eli Lilly shares rose nearly 10% on August 8 after second-quarter results beat Wall Street expectations. The pharmaceutical giant could post one other record quarter on October 30.
Potential data and regulatory approvals could also boost the stock price. Eli Lilly, for instance, expects the Food and Drug Administration to make a call by the tip of the yr on whether to approve Zepbound for sleep apnea.
According to an August 20 note from Leerink Partners analyst David Risinger, Eli Lilly may release data by yr's end from a late-stage trial pitting Zepbound directly against Novo Nordisk's Wegovy.
Please send suggestions, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
Latest technology in healthcare: Another continuous glucose monitor hits the market
It's raining continuous glucose monitors!
Abbott Laboratories announced Thursday that its first over-the-counter continuous glucose monitor, Lingo, is offered within the U.S., just days after its competitor Dexcom launched an identical product.
Continuous glucose monitors are small sensors which are punctured through the skin to measure glucose levels in real time. The devices are traditionally prescribed to diabetes patients because they will alert these users to emergencies. Lingo is more consumer-friendly since it is meant for adults who don’t take insulin.
Glucose is a sugar molecule that comes from food and is the body's principal source of energy. Everyone's glucose levels fluctuate, but persistently elevated levels can result in more serious conditions reminiscent of heart disease, insulin resistance and metabolic diseases, Abbott said.
Lingo is designed to assist users learn the way their body responds to food, exercise, sleep and stress and the way they will manage their glucose levels in healthier ways.
The U.S. Food and Drug Administration approved Lingo in June. It is offered over-the-counter and users should purchase one sensor for $49, two sensors for $89 or six sensors for $249 online.
Dexcom's recent over-the-counter continuous glucose monitor known as Stelo, and it was approved by the FDA in March. An ongoing Stelo subscription costs $89 per thirty days, and users can even purchase a month's supply without delay for $99.
I tested Stelo before it was launched and you may examine my experience here. I haven't tried Lingo yet, but Abbott explained the app and the way it really works to me.
One feature that particularly caught my eye is Abbott's “Lingo Count,” a measurement feature designed to assist users understand glucose spikes, which occur when the quantity of sugar within the bloodstream quickly rises after which falls again, often after eating.
The Lingo Count algorithm assigns a numerical value to every glucose spike to represent how big an impact that fluctuation is. Users have an overall Lingo Count goal that they need to stay below every day and may track their progress over time.
To learn how one can manage glucose spikes, Lingo users can take part in challenges and access learning materials within the app. I feel the challenges could possibly be a fun solution to make people more aware of their glucose levels and I'm fascinated by trying them out myself.
Overall, I discovered the app intuitive and helpful. The data is presented in a way that doesn't seem too complex or overwhelming, and consumers have the choice to drill down deeper in the event that they must.
I plan to check Lingo later this month, so I'll have more to share soon!
Feel free to send suggestions, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.
image credit : www.cnbc.com